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BACKGROUND: Successful cryopreservation of oocytes and embryos is essential not only to maximize the safety and efﬁcacy of ovarian
stimulation cycles in an IVF treatment, but also to enable fertility preservation. Two cryopreservation methods are routinely used: slow-
freezing or vitriﬁcation. Slow-freezing allows for freezing to occur at a sufﬁciently slow rate to permit adequate cellular dehydration while
minimizing intracellular ice formation. Vitriﬁcation allows the solidiﬁcation of the cell(s) and of the extracellular milieu into a glass-like state
without the formation of ice.
OBJECTIVE AND RATIONALE: The objective of our study was to provide a systematic review and meta-analysis of clinical outcomes
following slow-freezing/thawing versus vitriﬁcation/warming of oocytes and embryos and to inform the development of World Health
Organization guidance on the most effective cryopreservation method.
SEARCH METHODS: A Medline search was performed from 1966 to 1 August 2016 using the following search terms: (Oocyte(s) [tiab]
OR (Pronuclear[tiab] OR Embryo[tiab] OR Blastocyst[tiab]) AND (vitriﬁcation[tiab] OR freezing[tiab] OR freeze[tiab]) AND (pregnancy
[tiab] OR birth[tiab] OR clinical[tiab]). Queries were limited to those involving humans. RCTs and cohort studies that were published in
full-length were considered eligible. Each reference was reviewed for relevance and only primary evidence and relevant articles from the
bibliographies of included articles were considered. References were included if they reported cryosurvival rate, clinical pregnancy rate
(CPR), live-birth rate (LBR) or delivery rate for slow-frozen or vitriﬁed human oocytes or embryos. A meta-analysis was performed using a
random effects model to calculate relative risk ratios (RR) and 95% CI.
OUTCOMES: One RCT study comparing slow-freezing versus vitriﬁcation of oocytes was included. Vitriﬁcation was associated with
increased ongoing CPR per cycle (RR = 2.81, 95% CI: 1.05–7.51; P = 0.039; 48 and 30 cycles, respectively, per transfer (RR = 1.81, 95%
CI 0.71–4.67; P = 0.214; 47 and 19 transfers) and per warmed/thawed oocyte (RR = 1.14, 95% CI: 1.02–1.28; P = 0.018; 260 and 238
oocytes). One RCT comparing vitriﬁcation versus fresh oocytes was analysed. In vitriﬁcation and fresh cycles, respectively, no evidence for
a difference in ongoing CPR per randomized woman (RR = 1.03, 95% CI: 0.87–1.21; P = 0.744, 300 women in each group), per cycle
(RR = 1.01, 95% CI: 0.86–1.18; P = 0.934; 267 versus 259 cycles) and per oocyte utilized (RR = 1.02, 95% CI: 0.82–1.26; P = 0.873;
3286 versus 3185 oocytes) was reported. Findings were consistent with relevant cohort studies.
Of the seven RCTs on embryo cryopreservation identiﬁed, three met the inclusion criteria (638 warming/thawing cycles at cleavage and
blastocyst stage), none of which involved pronuclear-stage embryos. A higher CPR per cycle was noted with embryo vitriﬁcation compared
with slow-freezing, though this was of borderline statistical signiﬁcance (RR = 1.89, 95% CI: 1.00–3.59; P = 0.051; three RCTs; I2 =
71.9%). LBR per cycle was reported by one RCT performed with cleavage-stage embryos and was higher for vitriﬁcation (RR = 2.28; 95%
CI: 1.17–4.44; P = 0.016; 216 cycles; one RCT). A secondary analysis was performed focusing on embryo cryosurvival rate. Pooled data
from seven RCTs (3615 embryos) revealed a signiﬁcant improvement in embryo cryosurvival following vitriﬁcation as compared with slow-
freezing (RR = 1.59, 95% CI: 1.30–1.93; P < 0.001; I2 = 93%).
WIDER IMPLICATIONS: Data from available RCTs suggest that vitriﬁcation/warming is superior to slow-freezing/thawing with regard
to clinical outcomes (low quality of the evidence) and cryosurvival rates (moderate quality of the evidence) for oocytes, cleavage-stage
embryos and blastocysts. The results were conﬁrmed by cohort studies. The improvements obtained with the introduction of vitriﬁcation
have several important clinical implications in ART. Based on this evidence, in particular regarding cryosurvival rates, laboratories that con-
tinue to use slow-freezing should consider transitioning to the use of vitriﬁcation for cryopreservation.
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Introduction
Cryopreservation of gametes and embryos is an essential aspect of
ART. Its widespread application has allowed increased safety and efﬁ-
cacy of IVF treatments. The proportion of cryopreserved embryo
transfer cycles compared with fresh cycles is growing in Europe.
Overall it has been estimated that cryopreserved cycles contributed
to 32% of the transfers in 2011 compared to 28% in 2010. In some
countries, such as Switzerland, Finland, Netherlands, Sweden and
Iceland, the proportion of cryopreserved embryo transfers is higher
than 50% (Kupka et al., 2016). The observed differences among
European countries are mainly due to policies requiring lower trans-
fer order which, in turn, have led to more supernumerary embryos
available for cryopreservation (Coetsier and Dhont, 1998). The
recent systematic application of cryopreservation for new indications
such as cycle segmentation (i.e. planned freeze all) (Devroey et al., 2011),
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oocyte banking (Cobo et al., 2011a,2012) and pre-implantation
genetic testing at the blastocyst stage (Schoolcraft et al., 2011) likely
will contribute, in our opinion, to a further increase in the proportion
of cryopreserved cycles in the near future.
Embryo cryopreservation has, however, generated ethical, moral
and legal issues. Some countries have enacted speciﬁc laws that
restrict (e.g. Germany, Switzerland, Austria) or even forbid (Italy with
Law 40 in 2004) embryo cryopreservation. As an alternative and in
accordance with the legal prohibition of embryo cryopreservation,
oocyte cryopreservation had been introduced into routine practice in
Italy (La Sala et al., 2006; Borini et al., 2006a,b, 2007; Levi Setti,
2006; De Santis et al., 2007; Ubaldi et al., 2010). Not until 2009 did
the Italian Constitutional Court (151/2009) declare the constitution-
ality of embryo cryopreservation. Nevertheless, some couples are
concerned about the disposition of cryopreserved embryos
(Nachtigall et al., 2010) and therefore prefer to limit the number of
oocytes inseminated, with cryopreservation of the remainder (Heng,
2007). Oocyte cryopreservation also has emerged as an important
method for female fertility preservation for both medical and non-
medical indications (reviewed in De Vos et al., 2014 and Stoop et al.,
2014).
Since the ﬁrst pregnancy and delivery with cryopreserved embryos
(Trounson and Mohr, 1983; Zeilmaker et al., 1984), various protocols
have been introduced that differ from each other regarding the type
and concentration of cryoprotectants, equilibration timing, cooling
rates and cryopreservation devices used. Two principal approaches for
cryopreservation have been adopted: slow-freezing and vitriﬁcation
(reviewed by Edgar and Gook, 2012).
Slow-freezing allows for cryopreservation to occur at a sufﬁciently
slow rate to permit adequate cellular dehydration while minimizing
intracellular ice formation. The ﬁrst successful protocol applied in
1972 for mammalian embryo cryopreservation required a cooling
rate of ~1°C/min to −70°C (Whittingham et al., 1972). Embryo
cooling performed this way is referred to as equilibrium freezing
(Mazur, 1990). Subsequently, slow-rate cooling was only applied to
around −30°C (Willadsen, 1977). With this approach, intracellular
water content was converted into small intracellular ice crystals or
into a glass. To avoid extensive crystallization, a very rapid warming
was required.
Although the ﬁrst pregnancies with human cleavage-stage embryos
were obtained with the use of dimethylsulphoxide (DMSO) as the
cryoprotectant (Trounson and Mohr, 1983 and Zeilmaker et al.,
1984) this approach was rapidly replaced.
For nearly 20 years the protocol combining 1.5 M propylene glycol
(PROH) plus 0.1 M sucrose, as the permeable and non-permeable
cryoprotectants, respectively, has been the most widely used (Lassalle
et al., 1985; Testart et al., 1986). The freezing curve adopted requires
the use of a programmable freezing machine designed to provide
accurate and consistent cooling parameters. Brieﬂy, the sample is
exposed to a relatively rapid cooling rate of 2°C/min to around −7°C
followed by a manual seeding to induce ice crystal formation in the
solution. Then, a consistent slow cooling rate of 0.3–1.0°C/min is
applied before the freezing device is plunged into liquid nitrogen after
having reached temperatures around −40 to −70°C using the
approach of Trounson and Mohr (1983) or Lassale et al., (1985),
respectively. Modiﬁcations to the concentration of sucrose and the use
of other cryoprotectants such as glycerol have been investigated for
cryopreservation of oocytes, biopsied embryos and blastocysts (Cohen
et al., 1985; Fabbri et al., 2001; Jericho et al., 2003; Veeck et al., 2004).
Detailed analysis of biological principles and development of various
slow-freezing procedures have been described previously (Leibo and
Songstaken, 2002).
In contrast to slow-freezing, vitriﬁcation is a cryopreservation
method that allows solidiﬁcation of the cell(s) and the extracellular
milieu into a glass-like state without the formation of ice. The most
widely used vitriﬁcation method for mammalian embryos requires the
use of high initial concentrations of cryoprotectants, low volumes and
ultra-rapid cooling-warming rates. This approach was ﬁrst introduced
in human embryology for cleavage-stage embryos (Mukaida et al.,
1998) and then for oocytes (Kuleshova et al., 1999) and pronuclear-
stage embryos (Jelinkova et al., 2002; Selman and El-Danasouri,
2002). In the last 15 years several vitriﬁcation protocols have been
described, which differ from one another in the type of cryoprotec-
tants (Ethylene glycol [EG] and/or DMSO and/or PROH and sucrose
and/or Ficoll and/or Trehalose), equilibration and dilution para-
meters, the carrier tools and the cooling, storage and warming meth-
ods (reviewed in Vajta and Nagy, 2006). To date the most
commonly used protocol for both oocyte and embryo vitriﬁcation
involves the combination of 15% DMSO, 15% EG and 0.5 M sucrose
in a minimum volume (≤1 µl) (Kuwayama et al., 2005a,b). Other fun-
damental aspects of the technique are related to the cooling and
storing method. At present most embryos and oocytes are vitriﬁed
by exposing the sample to direct contact with liquid nitrogen (open
system) to increase the cooling/warming rates and thus the efﬁciency
of the procedure (Vajta et al., 2015). The ability to survive vitriﬁcation
is in fact strictly dependent on the degree of cellular dehydration and
on the rate of warming, rather than on the type and concentration of
cryoprotectants used (Jin and Mazur, 2015). High cryosurvival rates
of mouse oocytes and embryos have been recently obtained with the
use of only non-permeating cryoprotectant and a relatively slow cool-
ing rate, but combined with an ultra-rapid warming (Jin and Mazur,
2015). This study also demonstrates that the osmotic withdrawal of a
very large proportion of intracellular water prior to cooling, and not
the permeation of cryoprotectant in the cell, is the key for a success-
ful vitriﬁcation (Jin and Mazur, 2015).
To avoid potential contamination during open system vitriﬁcation,
sterile liquid nitrogen can be used (Vajta et al., 1998; Parmegiani et al.,
2009). Alternatively, speciﬁc devices have been designed to avoid dir-
ect contact of the samples with the nitrogen either during vitriﬁcation
(closed system) and/or during storage (Vajta et al., 1998; Kuleshova
and Shaw 2000; Isachenko et al., 2006; Vanderzwalmen et al., 2009;
Abdelhafez et al., 2011; Parmegiani, 2011). Of note, not all closed sys-
tems available on the market are completely free of any possible
sources of contamination (Vajta et al., 2015). On the other hand, a
lower degree of cooling/warming rate is generally associated with the
use of these systems. To date, neither open nor closed systems have
resulted in disease transmission during vitriﬁcation. However, to ensure
biosafety during cryopreservation, the use of sterile approaches is
recommended (Argyle et al., 2016), providing that adequate cooling
and, particularly, warming rates are still guaranteed.
The objective of the present study was to compare slow-freezing/
thawing versus vitriﬁcation/warming for cryopreservation of oocytes,
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embryos and blastocysts. RCTs and relevant observational cohort
studies were included in this systematic review and meta-analysis.
This study was performed to support a prioritized clinical question
and to provide a review of the evidence for debate and discussion
during the consultation for the development of the World Health
Organization (WHO) global guidelines: ‘Addressing evidence-based
guidance on infertility diagnosis, management and treatment.’
Methods
Oocyte cryopreservation: study eligibility
criteria
RCTs and well-designed cohort or case-control studies were included
that compared outcomes following slow-freeze versus vitriﬁcation of
mature i.e. metaphase II (MII) oocytes from women undergoing ART.
Given the paucity of studies making direct comparisons between the two
cryopreservation methods, studies comparing slow-freeze or vitriﬁcation
to fresh oocytes (control group) were also included. Only trials reported
in peer-reviewed full publications involving MII oocyte cryopreservation
were included; abstracts were excluded. Data from these studies were
used to assess the following outcomes: Clinical pregnancy rate (CPR),
live-birth rate (LBR) and oocyte cryosurvival rate when reported.
Oocyte cryopreservation: study search
methods
The searches for relevant studies were last performed and completed on 1
August 2016 by two review authors (AL, RM) using the following search
terms: (oocyte(s) [tiab]) AND (vitriﬁcation[tiab] OR freezing[tiab] OR
freeze[tiab]) AND (embryo quality[tiab] OR survival[tiab] OR pregnancy
[tiab] OR birth[tiab]). The search was limited to human studies. Articles
were also identiﬁed via snowball sampling by hand-searching references
from systematic reviews. The search returned 806 records, of which 88
were screened manually for relevance. The information about potentially
eligible studies was reported in a table describing the characteristics of the
studies for assessing the reliability of the results. Full texts of potentially eli-
gible studies were obtained and examined independently by the two differ-
ent authors; disagreements as to study eligibility were resolved by
discussion (all authors). A total of 20 references were included (Fig. 1a).
Oocyte cryopreservation: study descriptions
Slow-frozen versus vitriﬁed oocytes: clinical outcomes and
cryosurvival
One RCT was identiﬁed that randomized women to have an embryo
transfer from MII oocytes that were either slow-frozen or vitriﬁed (Smith
et al., 2010). Characteristics of this study are described in Table I. A total
of 230 patients with more than nine MII oocytes retrieved were allocated
by random number generator to either slow-freezing or vitriﬁcation. This
results in 30 cases of oocyte thawing and 48 cases of warming (average
ages at oocyte retrieval: 32 ± 1 and 31 ± 1 years (mean + SD), respect-
ively). LBRs were not reported. Ongoing CPRs were reported but not
deﬁned by minimum gestational age.
Two cohort studies were identiﬁed that compared CPRs from slow-
frozen versus vitriﬁed autologous oocytes (Fadini et al., 2009; Levi Setti
et al., 2014). Oocyte cryopreservation was performed in these studies in
an unselected population of infertile patients due to law restrictions (Law
40, 2004, Italy).
A secondary analysis was performed focusing on oocyte cryosurvival
rate. One RCT (Smith et al., 2010), two RCTs where sibling oocytes
were randomized, rather than patients, (Paffoni et al., 2008; Cao et al.,
2009) and three cohort studies (Fadini et al., 2009; Grifo and Noyes,
2010; Levi Setti et al., 2016) were included.
Slow-frozen versus fresh oocytes: clinical outcomes
No RCTs were identiﬁed comparing outcomes following transfer of
embryos from oocytes that were either slow-frozen or fresh. Five cohort
studies were identiﬁed comparing outcomes following transfer of
embryos derived from fresh or slow-frozen/thawed oocytes (Chamayou
et al., 2006; Levi Setti et al., 2006; Borini et al., 2007; Borini et al., 2010;
Virant-Klun et al., 2011).
Vitriﬁed versus fresh oocytes: clinical outcomes
One RCT was identiﬁed that randomized 600 donor recipients to trans-
fer of embryos either from fresh or vitriﬁed/warmed oocytes (Cobo
et al., 2010). Characteristics of this study are described in Table I.
Ongoing clinical pregnancy at 10–11 weeks of gestation was reported;
however, live-birth data were not reported.
Thirteen other studies were identiﬁed: ﬁve randomized sibling oocytes,
rather than patients, to vitriﬁcation versus fresh treatments (Cobo et al.,
2008; Rienzi et al., 2010; Parmegiani et al., 2011; Siano et al., 2013;
Forman et al., 2012), and eight cohort studies (Antinori et al., 2007; Nagy
et al., 2009; Almodin et al., 2010; Ubaldi et al., 2010; Garcia et al., 2011;
Trokoudes et al., 2011; Sole et al., 2013; Doyle et al., 2016). Three sibling
oocyte RCTs (Cobo et al., 2008; Siano et al., 2013; Forman et al., 2012)
and two cohort studies (Nagy et al., 2009 and Doyle et al., 2016) were
excluded from analysis due to study design (Forman et al., 2012) or data
reporting issues (Cobo et al., 2008; Nagy et al., 2009; Siano et al., 2013;
Doyle et al., 2016).
The remaining eight studies were grouped together for comparison of
clinical outcomes following transfer of embryos arising from oocytes that
were exclusively either vitriﬁed or fresh. Five meta-analyses (Oktay et al.,
2006; Cobo et al., 2011b; Cil et al., 2013; Glujovsky et al., 2014; Potdar
et al., 2014) focusing on oocyte cryopreservation were reviewed.
Embryo cryopreservation: study eligibility
criteria
RCTs and observational cohort studies were included that compared
slow-freeze to vitriﬁcation of pronuclear embryos, cleavage-stage
embryos or blastocysts from women undergoing ART. Only trials
reported in peer-reviewed full publications were included; abstracts were
excluded. The following outcomes were assessed: CPR, LBR and embryo
cryosurvival rate, when reported.
Embryo cryopreservation: study search
methods
The searches for relevant studies were last performed and completed on
August ﬁrst 2016 using the following search terms: (Pronuclear[tiab] OR
Embryo[tiab] OR Blastocyst[tiab]) AND (vitriﬁcation[tiab] OR freezing
[tiab] OR freeze[tiab]) AND (pregnancy[tiab] OR birth[tiab] OR clinical
[tiab]). The search was limited to human studies. Articles were also iden-
tiﬁed by hand searching references from systematic reviews. The search
returned 917 records, of which 587 were screened manually for rele-
vance. Full texts of potentially eligible studies were obtained and exam-
ined independently by two different authors (RM, DK); disagreements as
to study eligibility were resolved by discussion (all Authors). A total of 20
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studies were included for this analysis, comparing outcomes following
transfer of vitriﬁed versus slow-frozen embryos (Fig. 1b).
Embryo cryopreservation: study descriptions
Vitriﬁed versus slow-frozen embryos: clinical outcomes
Only one well-designed RCT comparing clinical outcomes following vitriﬁca-
tion versus slow-freezing between randomized women rather than embryos
was identiﬁed (Debrock et al., 2015). Two RCTs (Rama Raju et al., 2005
and Kim et al., 2000) comparing clinical outcomes between randomized
embryos were also included. Characteristics of these studies are described
in Table I. One additional RCT (Bernal et al., 2008) was excluded because
clinical outcomes were incomplete. Moreover, a meta-analysis (AbdelHafez
et al., 2010) focusing on clinical outcomes was reviewed. None of the
included studies compared cryopreservation techniques at the pronuclear-
stage. Two of the included RCTs were performed at the cleavage-stage
(Rama Raju et al., 2005; Debrock et al., 2015) and one at blastocyst stage
(Kim et al., 2000). The primary outcome measures chosen were CPR
and LBRs.
Eleven observational studies reporting clinical pregnancy per cycle
and/or per transfer of embryos at different stages of development were
pooled and analyzed (Kuwayama et al., 2005a,b; Stehilk et al., 2005;
Liebermann and Tucker, 2006; Rezazadeh Valojerdi et al., 2009; Wilding
et al., 2010; Sifer et al., 2012; Wang et al., 2012; Van Landuyt et al., 2013
and Liu et al., 2013; Zhu et al., 2015; Kaartinen et al., 2016). An
Figure 1 Flow charts for a systematic review and meta-analysis comparing slow-freezing versus vitriﬁcation of oocytes, embryos and blastocysts in
ART. (a) search for relevant studies for oocytes slow-freezing and vitriﬁcation (b) search for relevant studies for pronuclear, cleavage-stage embryo
and blastocyst slow-freezing and vitriﬁcation.
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Table I Characteristics of the included RCTs comparing reproductive outcomes of slow-freezing versus vitriﬁcation.
Authors
(year)
Location Study design Cryopreservation protocols Study
group
N° Control
group
N° Outcomes Risk of bias Journal: Impact
factor
Balaban
et al.
(2008)
Turkey Randomization
of embryos
Vitriﬁcation 16%PrOH + 16%
EG + 0.65 M sucrose + 10 mg/ml
Ficoll- open system
Cleavage
stage
vitriﬁcation
234
embryos
Cleavage
stage slow-
freezing
232
embryos
cryosurvival
rate,
blastocyct
formation
Serious risk of bias due to randomization
method, concealment of allocation,
blinding
Human
Reproduction:
4.621
Slow-freezing: 1.5 M PROH–0.1 M
Sucrose
Cao et al.
(2009)
China Randomization
of sibling
oocytes
Vitriﬁcation 15% EG + 15%
PROH + 0.5 M sucrose – open
system
Oocyte
vitriﬁcaiton
292
oocytes
Oocyte
slow-
freezing
123
oocytes
cryosurvival
rate
Serious risk of bias due to randomization
method, concealment of allocation,
blinding
Seminars in
Reproductive
Medicine: 2.113
Slow-freezing: 1.5 M
PROH + 0.3 M sucrose
Cobo et al.
(2010)
Spain Randomization
of patients
Vitriﬁcation 15% EG + 15%
DMSO + 0.5 M sucrose – open
system
Oocyte
vitriﬁcation
295
cycles
Oocyte
fresh
289
cycles
CPR,
cryosurvival
rate
No serious risk of bias Human
Reproduction:
4.621
Debrock
et al.
(2015)
Belgium Randomization
of patients
Vitriﬁcation 15% EG + 15%
DMSO + 0.5 M sucrose – closed
system
Cleavage
stage
vitriﬁcation
121
cycles
Cleavage
stage slow-
freezing
85
cycles
CPR, LBR,
cryosurvival
rate
No serious risk of bias Human
Reproduction:
4.621200
embryosSlow-freezing: 1.5 M PROH −
0.1 M Sucrose
217
embryos
Fasano
et al.
(2014)
Belgium Randomization
of embryos
Vitriﬁcation 20% EG + 15%
DMSO + 0.5 M sucrose – closed
system
Cleavage
stage
vitriﬁcation
516
cycles
Cleavage
stage slow-
freezing
260
cycles
CPR, LBR,
cryosurvival
rate
Serious risk of bias due to randomization
method, concealment of allocation, and
blinding
Journal of Assisted
Reproduction and
Genetics: 1.772660
embryos
395
embryosSlow-freezing: 1.5 M PROH −
0.1 M Sucrose
Huang
et al.
(2005)
Taiwan Randomization
of embryos
Vitriﬁcation 20% EG + 20%
DMSO and 0.5 M sucrose – open
system
Blastocyst
vitriﬁcation
81
embryos
Blastocyst
slow-
freezing
72
embryos
cryosurvial
rate
Serious risk of bias due to randomization
method, concealment of allocation,
blinding
Human
Reproduction:
4.621
Slow-freezing: 5% glycerol + 9%
glycerol 0.2 M sucrose
Kim et al.
(2000)
USA Randomization
of embryos
Vitriﬁcation 5.5 M EG + 1 M
sucrose
Blastocyst
vitriﬁcation
42
cycles
Blastocyst
slow-
freezing
216
cycles
CPR,
cryosurvival
rate
Unclear risk of bias related to random
sequence generation, allocation of
concealment acceptable, and blinding
Fertility and
Sterility: 4.426
Slow freezing: 5% glycerol and 9%
glycerol + 0.2 M sucrose
141
embryos
790
embryos
Paffoni
et al.
(2008)
Italy Randomization
of sibling
oocytes
Vitriﬁcation 15% DMSO, 15% EG,
and 0.5 M sucrose – closed
system
Oocyte
vitriﬁcation
90
oocytes
Oocyte
slow-
freezing
90
oocytes
Cryosurvival
rate
Serious risk of bias due to randomization
method, concealment of allocation,
blinding
Reproductive
Sciences: 2.429
Slow freezing: 1.5 mol/L PROH
and 0.3 mol/L sucrose
Parmegiani
et al.
(2011)
Italy Randomization
of sibling
oocytes
Vitriﬁcation 15% EG + 15%
DMSO + 0.5 M sucrose – open
system
Oocyte
vitriﬁcation
168
oocytes
Oocyte
Fresh
120
oocytes
Cryosurvival
rate
Serious risk of bias due to randomization
method, concealment of allocation, and
blinding
RBM online:2.796
Rama Raju
et al.
(2005)
India Randomization
of embryos
Vitriﬁcation 40% EG + 0.6 M
sucrose – open system
Cleavage
stage
vitriﬁcation
84
cycles
Cleavage
stage slow-
freezing
80
cycles
CPR,
cryosurvival
rate
Unclear risk of bias related to random
sequence generation, allocation of
concealment acceptable, and blinding
RBM online:2.796
127
embryos
Slow-freezing: 1.5 M PROH- 0.1 M
Sucrose
120
embryos
144
R
ienzietal.
additional two studies described by the authors as RCT’s were not truly
randomized studies and were therefore included in the analysis with
observational studies (Li et al., 2007 and Summers et al., 2016).
LBR per cycle and/or per transfer was reported in six studies
(Kuwayama et al., 2005a,b; Wilding et al., 2010; Wang et al., 2012; Liu
et al., 2013; Van Landuyt et al., 2013; Kaartinen et al., 2016).
Slow-frozen versus vitriﬁed embryos: survival
A secondary analysis was performed focusing on embryo cryosurvival
rate. Seven RCTs (Kim et al., 2000; Huang et al., 2005; Rama Raju et al.,
2005; Zheng et al., 2005; Balaban et al., 2008; Fasano et al., 2014;
Debrock et al.,2015) were included. Characteristics of these studies are
described in Table I. Moreover, 12 observational studies (Kuwayama
et al., 2005a,b; Stehilk et al., 2005; Liebermann and Tucker, 2006; Li
et al., 2007; Rezazadeh Valojerdi et al., 2009; Wilding et al., 2010; Sifer
et al., 2012; Wang et al., 2012; Van Landuyt et al., 2013 and Liu et al.,
2013; Zhu et al., 2015; Summers et al., 2016) and two meta-analyses
comparing results obtained with vitriﬁcation/warming and slow-freezing/
thawing (Loutradi et al., 2008; Kolibianakis et al., 2009) were identiﬁed.
Assessing the quality of each study
According to the WHO Handbook for Guideline Development (WHO,
2012) the quality of each study was assessed. In particular, each RCT was
evaluated for the following factors: how randomization was performed,
whether there was concealment of allocation, whether participants and
personnel were blinded to the intervention and outcome, whether there
was complete data reporting, whether an intention to treat analysis was
performed and whether any other potential sources of bias existed
(WHO, 2012). The overall risk of bias was classiﬁed as serious, not ser-
ious, or unclear and is presented in Table I for each randomized trial
included. The risk of bias is considered serious for all observational stud-
ies given the high risk for selection bias and confounding inherent in these
study designs.
Data synthesis and meta-analysis
Meta-analyses of studies were undertaken to estimate the pooled relative
risk ratios (RR) of outcomes including CPR per cycle, CPR per transfer and
cryosurvival of thawed/warmed oocytes or embryos. Statistical analyses
and construction of forest and funnel plots were performed with Stata ver-
sion 12.1 (StataCorp, TX, USA). RR and 95% CIs were calculated for each
outcome. A random effects model was used for the meta-analysis.
Heterogeneity was assessed with the use of the I2 test. Publication bias
was assessed by constructing funnel plots.
Assessment of the quality of the literature as
a whole
According to the WHO Handbook for Guideline Development (WHO,
2012) used to guide methodology in this systematic review, the quality of
the literature for each analysis was classiﬁed as high, moderate, low or
very low. A grade of high indicates that further research is very unlikely
to change conﬁdence in the estimate of effect; moderate indicates that
further research is likely to have an important impact on conﬁdence in
the estimate of effect and may change the estimate; low indicates that
further research is very likely to have an important impact on conﬁdence
in the estimate of effect and is likely to change the estimate; very low
indicates that any estimate of effect is very uncertain (WHO, 2012).
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Factors used to determine the classiﬁcation for any analysis took into
account the following factors: study design, consistency of the results
across the available studies, precision of the results (width of the CI), the
directness or generalizability of the results across populations, and the
likelihood of publications bias.
Results
Oocyte slow-freezing versus vitriﬁcation:
clinical outcomes and oocyte cryosurvival
A single RCT (Smith et al., 2010) revealed evidence of a difference in
favor of vitriﬁcation regarding ongoing pregnancy rate per cycle
(RR = 2.81, 95% CI: 1.05–7.51; P = 0.039; 48 and 30 cycles, vitriﬁca-
tion versus slow-freezing, respectively; low quality evidence) (Fig. 2a)
and per warmed/thawed oocyte (RR = 1.14, 95% CI: 1.02–1.28;
P = 0.018; 260 and 238 oocytes, vitriﬁcation versus slow-freezing,
respectively; low quality evidence). Limited evidence demonstrated
that clinical outcomes following vitriﬁcation versus slow-freezing were
similar when ongoing pregnancy rate was expressed per embryo trans-
fer (RR = 1.81, 95% CI: 0.71–4.67; P = 0.214; 47 and 19 transfers, vit-
riﬁcation versus slow-freezing, respectively; low quality evidence).
In two cohort studies (Fadini et al., 2009; Levi Setti et al., 2014)
the evidence also favored vitriﬁcation for CPR per cycle (RR = 1.72,
95% CI: 0.74–3.95; P = 0.212; 5460 and 9212 cycles, vitriﬁcation ver-
sus slow-freezing, respectively; I2 = 81.5%, very low quality evidence)
(Fig. 2b), per transfer (RR = 1.55, 95% CI: 0.82–2.92; P = 0.180, two
studies; I2 = 70.0%, very low quality evidence) and per warmed/
thawed oocyte (RR = 1.72, 95% CI: 0.84–3.52; P = 0.135; 26789
and 49264 oocytes, vitriﬁcation versus slow-freezing, respectively;
very low quality evidence). However, the differences were not statis-
tically signiﬁcant. Of note the CPR per cycle was relatively low in the
unselected population of patients undergoing autologous oocyte
cryopreservation due to law restrictions for both approaches, 11.8%
and 14.4% for slow freezing and vitriﬁcation, respectively.
The superiority of vitriﬁcation over slow-freezing was also observed
when cryosurvival rates of MII oocytes were compared. In three RCTs
(Paffoni et al., 2008; Cao et al., 2009; Smith et al., 2010) MII cryosurvi-
val rate was 82.3% (602/731) following vitriﬁcation/warming and
66.1% (298/451) following slow-freezing/thawing (RR = 1.23, 95% CI:
1.02–1.49; P = 0.031; three studies; 1182 oocytes thawed; I2 = 82.9%,
low quality evidence) (Fig. 2c). In the three cohort studies, cryosurvival
rate after vitriﬁcation was also signiﬁcantly higher than after slow-
freezing (RR = 1.23, 95% CI: 1.11–1.36, P < 0.001; three studies;
99 679 oocytes thawed; I2 = 91.6%, very low quality evidence) (Fadini
et al., 2009; Levi-Setti et al., 2016; Grifo and Noyes, 2010).
Oocyte slow-freezing versus fresh oocytes:
clinical outcomes
Analyses of the cohort studies (Chamayou et al., 2006; Borini et al.,
2010; Virant-Klun et al., 2011) in which sibling oocytes were not ran-
domized to be slow-frozen or used fresh revealed lower LBRs per
cycle with slow-freezing (RR = 0.49, 95% CI: 0.39–0.60; P < 0.0001;
three studies; 990 and 2271 cycles; I2 = 0.0%, very low quality evi-
dence) (Supplementary Fig. S1a), lower LBRs per transfer
(RR = 0.55, 95% CI: 0.44–0.68; P < 0.0001; three studies; 799 and
2046 cycles; I2 = 0.0%, very low quality evidence), and lower LBRs
per utilized oocyte (RR = 0.26, 95% CI: 0.21–0.32; P < 0.0001; three
studies; 5513 and 6670 cycles; I2 = 0.0%, very low quality evidence)
when slow-freeze was compared to fresh oocytes.
The CPR per cycle (RR = 0.42, 95% CI: 0.31–0.58; P < 0.0001;
ﬁve studies, 1809 and 3323 cycles, slow-freezing versus fresh,
respectively; I2 = 64.5%, very low quality evidence) (Supplementary
Fig. S1b), the CPR per transfer (RR = 0.45, 95% CI: 0.29–0.65, ﬁve
studies; P < 0.0001; 1534 and 2989 transfers; I2 = 78.5%, very low
quality evidence) and the CPR per utilized oocytes (RR = 0.29, 95%
CI: 0.25–0.35, four studies; 6600 and 9115 oocytes, slow-freezing
versus, fresh, respectively; P < 0.0001; I2 = 4.8%, very low quality
evidence) were all in favor of fresh oocytes as compared to slow-
frozen oocytes (Chamayou et al., 2006; Levi Setti et al., 2006; Borini
et al., 2007,2010; Virant-Klun et al., 2011). Each utilized slow-frozen
oocyte had a 2.27% (150/6600) likelihood of resulting in a pregnancy
in the population of women studied.
Oocyte vitriﬁcation versus fresh oocytes:
clinical outcomes
Analysis of a single RCT (Cobo et al., 2010) revealed no evidence for
a difference in ongoing CPR between the two groups when results
were expressed per woman randomized (RR = 1.03, 95% CI: 0.87–
1.21; P = 0.744, 300 women in each group; moderate quality evi-
dence), per cycle (RR = 1.01, 95% CI: 0.86–1.18; P = 0.934; 267 ver-
sus 259 cycles vitriﬁcation versus fresh, respectively; moderate quality
evidence) or per utilized oocyte (RR = 1.02, 95% CI: 0.82–1.26;
P = 0.873; 3286 versus 3185 oocytes, vitriﬁcation versus fresh,
respectively; moderate quality evidence).
The combined analysis of the cohort studies and the RCTs in
which sibling oocytes were randomized to be vitriﬁed or used fresh
(Sole et al., 2013; Parmegiani et al., 2011; Trokoudes et al., 2011)
revealed no evidence of a difference between cycles using exclusively
vitriﬁed versus fresh oocytes for LBR per cycle (RR = 1.04, 95% CI:
0.61–1.76, P = 0.892; three studies; 171 and 171 cycles, vitriﬁcation
versus fresh, respectively; I2 = 52.3%; very low quality evidence)
(Supplementary Fig. S2), LBR per oocyte utilized (RR = 2.35, 95% CI:
0.29–19.3, P = 0.427; two studies; 378 and 367 oocytes, vitriﬁcation
versus fresh, respectively; I2 = 58.5%; very low quality evidence)
(Parmegiani et al., 2011; Trokoudes et al., 2011), or LBR per transfer
(RR = 1.10, 95% CI: 0.64–1.88, P = 0.730; three studies; 166 and
170 transfers, vitriﬁcation versus fresh, respectively, I2 = 54.6%; very
low quality evidence). The two groups were also similar for CPR per
cycle (RR = 0.94, 95% CI: 0.81–1.10; P = 0.457; eight studies; 526
and 892 cycles, vitriﬁcation versus fresh, respectively; I2 = 22.9%,
very low quality evidence) (Sole et al., 2013; Antinori et al., 2007;
Almodin et al., 2010; Rienzi et al., 2010; Ubaldi et al., 2010; Garcia
et al., 2011; Parmegiani et al., 2011; Trokoudes et al., 2011); CPR
per transfer (RR = 0.97, 95% CI: 0.81–1.16; P = 0.714; seven st-
udies, 477 and 754 transfers, vitriﬁcation versus fresh, respectively;
I2 = 38.1%, very low quality evidence) (Sole et al., 2013; Antinori et al.,
2007; Almodin et al., 2010; Ubaldi et al., 2010; Garcia et al., 2011;
Parmegiani et al., 2011; Trokoudes et al., 2011); and CPR per oocyte
utilized (RR = 1.16, 95% CI: 0.57–2.69; P = 0.654; six studies; 1759
and 3832 oocytes, vitriﬁcation versus fresh, respectively; I2 = 89.5%,
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very low quality evidence) (Antinori et al., 2007; Almodin et al., 2010;
Ubaldi et al., 2010; Garcia et al., 2011; Parmegiani et al., 2011;
Trokoudes et al., 2011). Each utilized vitriﬁed oocyte had an 8.36%
(147/1759) likelihood of resulting in a pregnancy in the population of
women studied.
Embryo slow-freezing versus vitriﬁcation
Slow-freezing versus vitriﬁcation: CPR
Given the limited number of RCTs available, results obtained in three
RCTs with slow-freezing/thawing versus vitriﬁcation/warming for
Figure 2 Comparison of slow-freezing versus vitriﬁcation: oocytes. (a) Comparison based on CPR/cycle for oocytes: RCT; (b) Comparison based
on CPR/cycle for oocytes: cohort studies; (c) Comparison based on oocyte cryosurvival rate: RCTs. CPR, clinical pregnancy rate.
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cleavage-stage embryos and blastocysts (Kim et al., 2000; Rama Raju
et al., 2005; Debrock et al., 2015) were pooled. Overall, 638 warming/
thawing cycles (vitriﬁcation: n = 247; slow-freezing: n = 391) were
included. Data from pronuclear-stage warming cycles were not available.
A higher CPR per cycle was obtained with embryo vitriﬁcation com-
pared with slow-freezing though this was of borderline statistical signiﬁ-
cance (RR = 1.89, 95% CI: 1.00–3.58; P = 0.051, 638 cycles, three
RCTs; I2 = 71.9%, low quality evidence, Fig. 3a). However, a signiﬁcant
difference in favor of vitriﬁcation was observed when CPR per embryo
transfer was calculated (RR = 1.51, 95% CI: 1.03–2.23; P = 0.036; 488
embryo transfers; three RCTs; I2 = 35%, low quality evidence, Fig. 3b).
When pooling data from cohort studies (Kuwayama et al., 2005a,b;
Stehlik et al., 2005; Liebermann and Tucker, 2006; Li et al., 2007;
Rezazadeh Valojerdi et al., 2009; Wilding et al., 2010; Sifer et al., 2012;
Wang et al., 2012; Liu et al., 2013; Van Landuyt et al., 2013; Zhu et al.,
2015; Kaartinen et al., 2016), there was a signiﬁcantly higher CPR per
cycle (Supplementary Fig. S3a), but not per transfer, with vitriﬁcation
compared with slow-freezing (RR = 1.27, 95% CI: 1.05–1.55;
P = 0.015; eight observational studies; 8391 cycles; I2 = 76.5%, very
low quality evidence and RR = 1.07, 95% CI: 0.98–1.16; P = 0.16; 12
observational studies; 22 885 embryo transfers; I2 = 64.7%; very low
quality evidence, respectively).
When restricting the analysis of observational studies to those
including only cleavage-stage embryos (Kuwayama et al., 2005a,b;
Li et al., 2007; Rezazadeh Valojerdi et al., 2009; Wilding et al.,
2010; Sifer et al., 2012; Wang et al., 2012; Liu et al., 2013; Van
Landuyt et al., 2013; Zhu et al., 2015; Kaartinen et al., 2016), there
was no statistically signiﬁcant difference in CPR per cycle or CPR
per transfer with vitriﬁcation compared with slow-freezing
(RR = 1.27, 95% CI: 1.00–1.55; P = 0.62; six observational stud-
ies; 7789 cycles; I2 = 78.8%, very low quality evidence and
RR = 1.05, 95% CI: 0.95–1.16; P = 0.33; 10 observational studies;
17 448 embryo transfers; I2 = 67%; very low quality evidence,
respectively).
When restricting the analysis of observational studies to those
including only blastocyst stage embryos (Kuwayama et al., 2005a,b;
Stehlik et al., 2005; Liebermann and Tucker, 2006), there was no
statistically signiﬁcant difference in CPR per cycle or CPR per transfer
with vitriﬁcation compared with slow-freezing (RR = 1.51, 95% CI:
0.69–3.29; P = 0.31; two observational studies; 602 cycles; I2 =
78.8%, very low quality evidence and RR = 1.16, 95% CI: 0.89–1.50;
P = 0.27; three observational studies; 5437 embryo transfers; I2 =
61.8%; very low quality evidence, respectively).
Slow-freezing versus vitriﬁcation LBR
The LBR per cycle and per transfer was reported in only one RCT
performed with embryos at the cleavage-stage (Debrock et al.,
2015), with higher rates observed for vitriﬁcation (RR = 2.28; 95%
Figure 3 Comparison of slow-freezing versus vitriﬁcation: embryos. (a) Comparison of slow-freezing versus vitriﬁcation on CPR/cycle for
cleavage-stage embryos and blastocysts: RCTs; (b) Comparison of slow-freezing versus vitriﬁcation on CPR/embryo transfer for cleavage-stage
embryos and blastocysts: RCTs.
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CI: 1.17–4.44; P = 0.016; 216 cycles; low quality evidence and
RR = 1.862 95% CI: 0.97–3.58; P = 0.062; 179 embryo transfers;
low quality evidence, respectively).
Only three observational trials reported LBR per cycle (Wilding
et al., 2010; Wang et al., 2012; Van Landuyt et al., 2013)
(Supplementary Fig. S3b) and six reported LBR per transfer (Kuwayama
et al., 2005a,b; Wilding et al., 2010; Wang et al., 2012; Liu et al., 2013;
Van Landuyt et al., 2013; Kaartinen et al., 2016). No differences were
observed between vitriﬁcation and slow-freezing (RR = 1.05, 95% CI:
0.67–1.65; P = 0.831; 1621 cycles; I2 = 74.8%; very low quality evi-
dence and RR = 1.03, 95% CI: 0.91–1.18; P = 0.62; 14 996 embryo
transfers; I2 = 45.8%; very low quality evidence, respectively).
When restricting the analysis of observational studies to those
including only cleavage-stage embryos (Kuwayama et al., 2005a,b; Li
et al., 2007; Rezazadeh Valojerdi et al., 2009; Wilding et al., 2010;
Sifer et al., 2012; Wang et al., 2012; Liu et al., 2013; Van Landuyt
et al., 2013; Zhu et al., 2015; Kaartinen et al., 2016), there was no
signiﬁcant difference in LBR per cycle or LBR per transfer with vitriﬁ-
cation compared with slow-freezing (RR = 1.05, 95% CI: 0.67–1.65;
P = 0.83; three observational studies; 1621 cycles; I2 = 74.8%, very
low quality evidence and RR = 1.02, 95% CI: 0.87–1.20; P = 0.77;
ﬁve observational studies; 10 153 embryo transfers; I2 = 52.7%; very
low quality evidence, respectively).
When restricting the analysis of observational studies to those
including only blastocyst stage embryos (Kuwayama et al., 2005a,b;
Stehlik et al., 2005; Liebermann and Tucker, 2006), there was no sig-
niﬁcant difference in LBR per cycle with vitriﬁcation compared with
slow-freezing (RR = 1.10, 95% CI: 0.87–1.40; P = 0.42; 1 observa-
tional study; 4843 cycles; very low quality evidence).
Slow-freezing versus vitriﬁcation: embryo cryosurvival
Data were pooled from the seven RCTs (Kim et al., 2000; Huang et al.,
2005; Rama Raju et al., 2005; Zheng et al., 2005; Balaban et al., 2008;
Fasano et al., 2014; Debrock et al., 2015) involving 3615 cleavage-stage
embryos and blastocysts (slow-freezing: n = 2061; vitriﬁcation: n =
1554). The analysis revealed that vitriﬁcation was associated with a sig-
niﬁcant improvement in embryo cryosurvival (RR = 1.59, 95% CI: 1.30–
1.93; P < 0.001; I2 = 93%; moderate quality evidence) (Fig. 4).
When restricted to cryosurvival of only cleavage-stage embryos,
vitriﬁcation was superior to slow-freezing (RR = 1.74, 95% CI: 1.39–
2.18; 2531 embryos; P < 0.001; I2 = 92.2%; moderate quality evi-
dence) (Rama Raju et al., 2005; Zheng et al., 2005; Balaban et al.,
2008; Fasano et al., 2014; Debrock et al., 2015). Post-warming cryo-
survival rates of vitriﬁed blastocysts were also higher than those
observed with slow-freezing, but did not reach statistical signiﬁcance
(RR = 1.25: 95% CI: 0.93–1.67; P = 0.13; two RCTs; 1084 blasto-
cysts; I2 = 82.2%, moderate quality evidence).
Twelve cohort studies (Kuwayama et al., 2005a,b; Stehlik et al., 2005;
Liebermann and Tucker, 2006; Li et al., 2007; Rezazadeh Valojerdi
et al., 2009; Wilding et al., 2010; Sifer et al., 2012; Wang et al., 2012;
Liu et al., 2013; Van Landuyt et al., 2013; Zhu et al., 2015; Summers
et al., 2016) with 64 982 cryopreserved pronuclear stage, cleavage-stage
embryos or blastocysts were identiﬁed. The pooled data showed that
vitriﬁcation was associated with a signiﬁcant improvement in embryo
cryosurvival (RR = 1.12, 95% CI: 1.07–1.18; P < 0.001; I2 = 98.6% very
low quality evidence) (Supplementary Fig. S4). When stratiﬁed by
embryo stage, the cryosurvival rates favored vitriﬁcation for both
cleavage-stage embryos (RR = 1.14, 95% CI: 1.07–1.22; P < 0.001; 10
cohort studies; 49 200 embryos; I2 = 99%; very low quality evidence)
and blastocysts (RR = 1.08, 95% CI: 1.02–1.15; P = 0.005; three cohort
studies; I2 = 70.0%, very low quality evidence).
Discussion
The principal ﬁndings of this systematic review and meta-analysis
support vitriﬁcation as being superior to slow-freezing for cryopreser-
vation of both human oocytes and embryos in clinical ART. While
the quality of the evidence for clinical outcomes comparing the two
cryopreservation methods was mostly low and based on clinical preg-
nancy, rather than live-birth, that for post-thaw cryosurvival of
oocytes and embryos was moderate.
The introduction of vitriﬁcation over the last decade and its exten-
sive application has improved human oocyte and embryo cryosurvival
rates and clinical outcomes after replacement of embryos cryopre-
served at different stages of development. As shown in this study,
recent evidence has revealed that this technique has closed the gap
Figure 4 Comparison of slow-freezing versus vitriﬁcation on cryosurvival rate for cleavage-stage embryos and blastocysts: RCTs.
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between fresh and cryopreserved oocytes in good-prognosis patients.
However, although vitriﬁcation has allowed a substantial improve-
ment in oocyte cryosurvival, when applied in an unselected popula-
tion of patients (e.g. as a result of law) the clinical outcomes
remained generally low (Fig. 2b). For embryo and blastocyst cryosur-
vival, available data suggest an improvement with the use of vitriﬁca-
tion compared to slow-freezing, albeit over a wide range (30–93%).
Accordingly, a typical laboratory could improve from ~60% embryo
cryosurvival rate using slow-freezing to 78–100% embryo cryosurvival
rate using vitriﬁcation. A beneﬁcial treatment effect was also identi-
ﬁed in RCTs for CPRs and LBRs per embryo and/or blastocyst
warming cycle and per transfer.
Due to the improved cryosurvival outcomes with vitriﬁcation
(Evans et al., 2014; Argyle et al., 2016) many laboratories worldwide
have completely replaced slow-freezing with vitriﬁcation. It is there-
fore unlikely that additional prospective comparisons with current
protocols will be performed.
The optimized oocyte/embryo/blastocyst cryosurvival rates and
clinical outcomes achieved with the use of vitriﬁcation have important
clinical implications, which together allow a personalized approach in
the care of different patient populations (Fig. 5).
Contribution of cryopreservation to the
cumulative LBR
Cryopreserved embryo transfers contribute substantially to the total
success rate of an IVF cycle. Cumulative live birthrate (CLB) is
deﬁned as the likelihood of having an offspring after the utilization of
all retrieved oocytes and associated embryos, thereby involving the
transfer of fresh as well as all cryopreserved embryos. CLB is
acknowledged as the most appropriate outcome measure in IVF to
be used by practitioners and health administrators (Tiitinen et al.,
2001). It has been estimated that in Europe in 2011 cryopreservation
contributed to the overall LBR by 4% (LBR increasing from 19.7%
with only fresh cycles to 24.0% including cryo-cycles) (Kupka et al.,
2016). In countries where cryopreservation is systematically applied,
the contribution is even more apparent: Finland +13.4%, Switzerland
+10.2% and Australia and New Zealand +13.5% (Macaldowie et al.,
2012; Kupka et al., 2016). These data reﬂect improvements obtained
in embryo culture, cryopreservation technologies and/or the adop-
tion of a more conservative embryo transfer policy (i.e. when fewer
embryos are transferred in fresh cycles, more are available for
cryopreservation).
Embryo transfer policy and cryopreservation
Considerable differences exist in embryo transfer policies across the
world. Where not legally restricted, the number of embryos transferred
simultaneously depends upon clinical decision-making, reimbursement
strategies and other ﬁnancial considerations and competency in cryo-
preservation technologies. Despite a general trend towards transferring
fewer embryos (Clua et al., 2012), the mean percentage of single
embryo transfers was only 27% in Europe in 2011 (Kupka et al., 2016)
and 17% in the USA (CDC, 2011). On the other hand, in Australia and
New Zealand, single embryo transfer is performed in more than 75% of
cycles (Macaldowie et al., 2012). The incidence of multiple pregnancies,
an unavoidable outcome of IVF when more than one embryo is
transferred, is strongly correlated to the embryo transfer policy and
varies from 19.8% in USA (CDC, 2011) and 19.2% in Europe (Kupka
et al., 2016) to 6.5% in Australia and New Zealand (Macaldowie
et al., 2012).
The main reasons for transferring more than one embryo are asso-
ciated with the relative low efﬁciency of IVF, the poor prediction for
embryo implantation potential and concerns regarding the quality of
cryopreservation programmes. Other motivations are also related to
the emotional and ﬁnancial burden of ART treatment and lack of
strong guidelines or regulatory bodies concerning embryo transfer
policy (ESHRE Campus report 2001). In this context, it is clear that
improvements in embryology technologies, including embryo assess-
ment and cryopreservation protocols, are essential for promoting sin-
gle embryo transfer policies with an aim to reduce the maternal and
neonatal risks associated with multiple gestations. Of note, elective
single embryo transfer policy combined with enhanced embryo selec-
tion and vitriﬁcation is also a realistic option in poor-prognosis
patients of advanced maternal age (Ubaldi et al., 2015).
IVF cycle segmentation
A new strategy, called ‘cycle segmentation’, has recently been pro-
posed that comprises a planned ‘freeze all’ of all oocytes and/or
embryos. In this setting ovarian stimulation is optimized, including
ﬁnal oocyte maturation triggering with GnRH agonist in an antagonist
cycle, all oocytes and/or embryos are cryopreserved (segment A)
and later transferred to a receptive endometrium in a subsequent
cycle (segment B) (Devroey et al., 2011). This approach has been
tested with cryopreserved oocytes, pronuclear-stage and/or cleaved
embryos in patients at risk of ovarian hyperstimulation syndrome
(OHSS) (Griesinger et al., 2007,2011; Herrero et al., 2011). With this
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strategy, the risk of OHSS can be almost eliminated (Fatemi et al.,
2010; Youssef et al., 2014).
Furthermore, transfer of exclusively cryopreserved single blasto-
cysts in a population-based cohort study was found to decrease the
risk of ectopic pregnancy (Li et al., 2015) and increase IVF success
rates with no increase in adverse perinatal outcomes (Li et al., 2014).
Improvements of clinical and ongoing pregnancy rates with the use of
cryopreserved compared to fresh embryos have been reported in a
recent meta-analysis (Roque et al., 2013). Additionally, similar efﬁcacy
was found in an RCT comparing outcomes following fresh transfer to
that following freeze-all at either the blastocyst or the pronuclear-
stage (Shapiro et al., 2015). Although cryopreservation cannot guar-
antee the survival of all embryos, these results clearly underscore the
utility of cryopreservation in increasing the safety of IVF treatments,
especially among high-responder patients, without affecting the cumu-
lative pregnancy rate.
Cryopreservation and enhanced embryo
evaluation
Embryo evaluation continues to be performed primarily by morpho-
logical assessment and/or morphokinetic analysis at different stages
of development. However, static and dynamic morphological evalua-
tions have limited clinical value (Guerif et al., 2007; Racowsky et al.,
2009; Kaser and Racowsky 2014). Signiﬁcant improvements in
implantation rates in different patient populations have been obtained
by the introduction of chromosomal aneuploidy testing at the blasto-
cyst stage (Dahdouh et al., 2015; Lee et al., 2015). This strategy com-
bines different procedures including blastocyst culture, biopsy and
cryopreservation. The improvements in cryosurvival rates achieved
with vitriﬁcation of biopsied blastocysts (Escriba et al., 2008; Zhang
et al., 2009) have provided an important contribution to the wide-
spread implementation of this technology. Future challenges in
embryology will deal with further enhancement of embryo evaluation
beyond aneuploidy testing and to identify the patient populations
best served by such testing. Several studies are currently ongoing that
investigate correlations among ‘-omic’ proﬁling, metabolism, spent
culture media analysis and embryo quality (reviewed in Gardner
et al., 2015). These studies offer promise in the coming years to
increase the predictive power for implantation. The availability of reli-
able vitriﬁcation protocols for cryopreservation allows an extension
of time available for embryo evaluation by such indirect measures,
thereby affording a potential for implementation of new validated
approaches for embryo selection.
New possibilities related to oocyte
cryopreservation
Oocyte cryopreservation is a relatively new technology in ART but
has already important indications. One of the most common applica-
tions of oocyte cryopreservation is for oocyte donation programmes.
The introduction of oocyte banks offers different advantages including
reduced waiting time, no need for patient synchronization, improved
safety to prevent disease transmission and the possibility to increase
donor pools. The increased availability of vitriﬁed donor eggs has, in
turn, allowed the widespread application of oocyte donation and the
implementation of new forms of collaboration between centres (even
when located in different countries). For example, an egg bank may
provide donor evaluation and screening, ovarian stimulation, oocyte
retrieval and cryopreservation, and then release these cryopreserved
donor oocytes for recipient use at associated IVF clinics (Nagy et al.,
2015). Consequently, oocyte vitriﬁcation has provided important
beneﬁts for patients requiring donation, especially in those countries
where there is a lack of donors.
Oocyte cryopreservation can be used as a new strategy to accu-
mulate oocytes in poor-responder patients (Cobo et al., 2012). It is
also a back-up procedure, which can be performed in case of failure
to obtain a semen sample on the day of oocyte retrieval.
The developments in oocyte cryopreservation after the introduc-
tion of vitriﬁcation have also increased incentives to offer fertility
preservation for patients receiving gonadotoxic therapies for cancer
or other medical diseases (ASRM 2013; De Vos et al., 2014). The
possibility of preserving oocytes is of considerable importance in this
context. Oocyte cryopreservation, instead of the use of male-partner/
donor sperm to create embryos, allows the possibility of reproductive
autonomy in women without partners at the time when their fertility
preservation is desired (Rienzi and Ubaldi, 2015). Finally, oocyte vitri-
ﬁcation can also be used for elective fertility preservation for women
who are conscious of the decline in oocyte quality and quantity with
advancing maternal age but who are not ready to become pregnant
(Stoop 2011).
Of note, when oocyte cryopreservation is imposed by law restric-
tions and applied to an unselected population of infertile patients the
clinical outcomes are compromised.
Standardization of protocols and automation
Unlike slow-freezing, vitriﬁcation does not require a programmable
freezing machine to provide speciﬁc cooling parameters. The technique
is exclusively manual and is thus operator dependent. Furthermore, dif-
ferent commercial kits for vitriﬁcation are available and differ with
respect to the solutions and devices utilized. Vitriﬁcation effectiveness
may thus be highly variable and dependent on the protocols and
experience of a laboratory. The heterogeneity of methods applied can
create challenges with transportation of vitriﬁed samples between
laboratories using different cryoprotectant mixtures and/or vitriﬁcation
devices. A rigorous process of standardization is therefore advocated.
Comparative studies should be undertaken to establish best practices
that would then be adopted universally (as occurred for slow-freezing
30 years ago). Indeed, attempts to promote standardization, consi-
stency and efﬁciency are already underway with the introduction
of automation (Roy et al., 2014). However, this approach requires
considerable ﬁnancial investment and its implementation is thus still
limited.
Obstetric and perinatal outcomes
Although cryopreservation of oocytes and embryos is now a well-
established procedure, long-term follow-up studies of children are
still sparse. Data from systematic reviews and individual cohort stud-
ies are mostly reassuring, suggesting that pregnancies obtained from a
cryopreserved oocyte and/or embryo transfer are not associated
with increased perinatal risks compared with those resulting from
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fresh embryo transfer (Wang et al., 2005; Chian et al., 2009; Noyes
et al., 2009; Wennerholm et al., 2009; Cobo et al., 2010; Pelkonen
et al., 2010; Pinborg et al., 2010; Maheshwari et al., 2012; Levi-Setti
et al., 2013; Liu et al., 2013; Cobo et al., 2014; Belva et al., 2016; De
Munch et al., 2016; Levi-Setti et al., 2016). Obstetric and perinatal
complications (e.g. antepartum haemorrhage, preterm birth, small for
gestational age, low birthweight and perinatal mortality) are even
lower when frozen or vitriﬁed embryos are replaced, likely as a con-
sequence of the natural uterine environment that may better support
early placentation and embryogenesis (Wennerholm et al., 2009;
Maheshwari et al., 2012; Belva et al., 2016). Moreover, further
reassuring evidence comes from studies evaluating the safety of
oocyte vitriﬁcation in oocyte donation programmes (Chian et al.,
2009; Noyes et al., 2009; Cobo et al., 2010; Cobo et al., 2014; De
Munch et al., 2016) and in fertility preservation patients (Martinez
et al., 2014).
Conclusions
Cryopreservation is an essential component in the treatment of
patients undergoing ART and should be optimized in every IVF
laboratory, as it allows for increased cumulative LBRs and offers the
possibility to reduce multiple gestations and OHSS risk. According to
the available evidence appraised in this systematic review and meta-
analysis, vitriﬁcation is the best strategy for cryopreservation of all
developmental stages from mature oocyte to embryos at the blasto-
cyst stage. As this technique signiﬁcantly increases oocyte and
embryo cryosurvival rates when compared to slow-freezing, it has led
to an improvement in clinical outcomes in cryopreserved cycles and
also has made fertility preservation and donor oocyte banks a viable
option for patients. Furthermore, it allows for reliable segmentation
of the IVF cycle by temporally disconnecting the stimulation process
from embryo transfer; consequently, this affords additional time for
new invasive and non-invasive methods of embryo selection. Finally, if
standardized and/or automated, the consistency and efﬁciency of the
technique would likely be assured across all laboratories.
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